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Abstract
Background: Dispensations of opioid analgesics to patients on opioid agonist therapy (OAT) may increase the risk
of overdoses. The current study’s objectives are to investigate the dispensation rates and mean daily doses of
dispensed opioid analgesics among patients who received OAT opioids in Norway during 2013–2017 and evaluate
whether discontinuing OAT opioids affects the dispensed dose of opioid analgesics.
Methods: Information on opioids was collected from the Norwegian Prescription Database. Dispensation rates
were calculated by dividing the number of patients who were dispensed at least one opioid analgesic by the
number of patients who were dispensed an OAT opioid. We calculated the mean daily dose of opioid analgesics in
oral morphine equivalents. The OAT opioid dose was defined as a ratio between the dispensed doses divided by
the mean recommended dose. We used logistic regression to estimate the association between the dispensation of
an opioid analgesic, a dose of OAT opioids, having chronic pain, and being on palliative care.
Results: A total of 10,371 patients were dispensed at least one OAT opioid during the study period. In 2017, 18%
were dispensed an opioid analgesic with a mean daily dose of 29 mg of oral morphine equivalents. Being
dispensed an opioid analgesic was associated with having chronic pain (adjusted odds ratio (aOR): 3.6, 95%
confidence interval: 3.2–4.2), being on palliative care (aOR: 6.1, 4.7–7.9), and receiving an OAT opioid dose below
half of the recommended OAT dose (aOR: 1.7, 1.4–2.0). Similar results were seen in 2013–2016. The discontinuation
of OAT opioids could increase the dose of dispensed opioid analgesics.
Conclusion: Reducing the dispensation of opioid analgesics can be achieved by increasing the OAT opioid dose
for patients on a low OAT dose, and by extending the period needed to taper off the OAT opioid dose at
discontinuation.
Keywords: Opioid substitution treatment, Drug prescriptions, Opioid analgesics, Treatment outcome, Chronic pain,
Palliative care
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Background
At least 50% of all patients undergoing opioid agonist
therapy (OAT) have somatic or mental comorbidities
[1, 2], and more than 60% have physical comorbidities
such as infections, and physical injuries that may
require opioid analgesics (e.g. morphine, oxycodone,
and ketobemidone) [2, 3]. High opioid tolerance and
potentially significant individual differences in the dose
needed to achieve pain relief make patients on OAT
particularly challenging to treat adequately with opioid
analgesics [4]. Therefore, co-dispensation, combining
both opioid analgesics and OAT opioids (buprenorphine
and methadone), are often required to suppress pain and
treat opioid dependence on OAT. However, more than
20% percent of patients on OAT have psychiatric disor-
ders such as attention deficit hyperactivity disorder [5],
personality disorders [1], or psychosis diseases, and nearly
50% have other drug dependencies that may influence
their ability to follow up the dispensed opioid analgesics
as dosed [6, 7]. In these cases, concomitant dispensations
of several opioids may potentially affect the risk of over-
dose deaths and intoxications, as well as aggravate pain if
the opioids are not handled correctly [8–10].
Buprenorphine and methadone are the most frequently
dispensed opioids in OAT worldwide. They are chosen due
to their safety and long duration of action, and only one
administration daily is needed [11–15]. Opioid analgesics
are short and intermediate-acting agents that generally lack
these properties, and they are thus not recommended for
long-term therapy to support recovery from opioid depend-
ence [8, 11, 16–18]. However, many OAT patients have
chronic pain related comorbidities, and some receive pallia-
tive care, which may make the co-dispensations of opioid
analgesics and OAT opioids essential [4, 19]. Balancing
between achieving adequate pain relief and stabilizing the
OAT rehabilitation is, in these contexts, challenging. Never-
theless, there has been limited research on dispensations of
opioid analgesics to patients on OAT and the characteris-
tics of patients dispensed opioid analgesics and OAT opi-
oids concomitantly [20].
Norway experiences many of the same opioid-related
complications as the United States, with high crude
mortality rates related to opioid dependence and over-
dose [10, 21]. For a substantial proportion of these
patients, OAT is an essential approach. In Norway,
about 7500 patients received OAT opioids in 2017, and
about 700 left treatment [22]. Of those who underwent
OAT in the period 2007–2008, 12% were dispensed
opioid analgesics [8], while the proportion of patients
who left OAT and were dispensed opioid analgesics after
discontinuation is unknown. By comparison, a recent
Canadian study shows that 18% of patients who received
methadone during OAT between 2003 and 2010 were
dispensed opioid analgesics [9, 23]. In recent years,
national programs in Norway have focused on cautious
dispensation practices regarding opioid analgesics in order
to reverse the opioid dependence epidemic [21, 24]. To
complement this, more knowledge of the circumstances
surrounding dispensed opioid analgesics in the OAT
population is needed to be able to customize OAT for
patients with severe opioid dependence.
Thus, this observational study aims to evaluate dispensed
opioid analgesics among patients who were dispensed at
least one OAT opioid (methadone or buprenorphine) in
Norway between 2013 and 2017 by using national register-
based data. More specifically, we will:
1. Calculate the dispensation rates and doses of
dispensed opioid analgesics among patients who
were dispensed at least one OAT opioid per
calendar year.
2. Calculate, using logistic regression models per
calendar year, whether the dispensation of an
opioid analgesic was associated with age, gender,
chronic pain, palliative care, and the number, type,
and mean daily dose of dispensed OAT opioids
among patients who were dispensed an OAT
opioid.
3. Evaluate the dispensation rates and mean daily




All data used were national register data drawn from the
Norwegian Prescription Database (NorPD) (www.norpd.
no). From January 1, 2004, all pharmacies in Norway are
obliged to submit all dispensed drug data electronically to
the Norwegian Institute of Public Health. NorPD contains
information concerning all drugs, including reimburse-
ments, dispensed from pharmacies in Norway, except for
dispensations that occur during hospitalization or at
outpatient clinics. The Anatomical Therapeutic Chemical
(ATC) classification system was employed according to
determination by the World Health Organization (WHO)
Collaborating Centre for Drug Statistics Methodology per
October 2018 [25]. The NorPD data used in this study
were collected from January 1, 2013 to March 31, 2018.
The STROBE checklist was applied in preparation for the
study (Additional file 1).
Study population
We included all patients above 18 years of age who were
dispensed at least one OAT opioid – including methadone,
levomethadone, buprenorphine, and buprenorphine-
naloxone – in the period January 1, 2013 to December 31,
2017. Patients who were dispensed methadone tablets to
achieve pain relief in palliative care were excluded. These
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were identified in the data as those who were dispensed
methadone tablets without any dispensations of other OAT
opioids or methadone mixtures during the period from
January 1, 2004, to December 31, 2017. We defined discon-
tinuation of OAT as any patient who had their last dispen-
sation of an OAT opioid within the inclusion period
January 1, 2017 to September 30, 2017, with no further dis-
pensations until the end of the NorPD data collection
period on March 31, 2018. Any patient who died was
excluded from the calendar year of their death.
Analysis strategy and statistical analyses
Definitions of OAT opioids, opioid analgesics, age, chronic
pain, palliative care, type and number of dispensations, and
doses of OAT opioid and dispensed opioid analgesics
During the study, we defined opioid agonist therapy opi-
oids and opioid analgesics according to their ATC codes
(Additional file 2) and categorized all patients into age
groups: ≤ 25, 26–35, 36–45, 46–55, and ≥ 56. We de-
fined ‘patients with chronic pain’ as those who were dis-
pensed drugs during the study period for reimbursement
due to chronic pain. Similarly, ‘patients on palliative
care’ were defined as all patients who were dispensed
drugs for reimbursement due to palliative care between
2013 and 2017. Patients who were dispensed drugs for
reimbursement concerning both chronic pain and pallia-
tive care were categorized as ‘patients on palliative care’.
Moreover, the type of OAT opioid was defined as the
last type dispensed per calendar year. The number of
dispensations of an opioid was defined as all dispensa-
tions of a drug. Furthermore, we calculated the doses of
dispensed opioid analgesics and OAT opioids by using
the daily defined dose (DDD) stated in NorPD and
defined by the WHOs standards (Additional file 3) [25].
For opioid analgesics, we summarized all dispensed
DDD per opioid per calendar year and converted the
total DDDs into milligrams. Further, we calculated all
the dispensed milligrams per opioid and converted them
to oral morphine equivalents (OMEQ) based on equipo-
tency [26]. The total sum of all dispensed morphine
equivalents per patient was summarized per year and
divided by 365.25 days. For OAT opioids, we calculated
an OAT opioid dose ratio based on the mean dispensed
OAT opioid dose per day and divided by the mean
recommended dose for OAT per day. We defined a
mean recommended OAT opioid dose as the mean dose
needed to support the recovery from the opioid depend-
ence per day as defined by WHOs recommendations: 90
mg methadone, 45 mg levomethadone, 18 mg buprenor-
phine, or 18/4.5 mg buprenorphine-naloxone [27]. The
dispensed OAT opioid dose per day was calculated by
summarizing all DDD of each OAT opioid per year. The
OAT opioids were converted from DDD to milligrams
according to the WHOs standard [25]. Further, the
milligrams were divided by 365.25 days and the mean
recommended dose per day. Finally, the OAT opioid
dose ratio from each OAT opioid was summarized to
the OAT opioid dose ratio.
The OAT opioids were also categorized into four
dispensation groups per year: 1–6 (less than every
second month), 7–12 (less than monthly), 13–51 (at
least monthly), and ≥ 52 (at least weekly). For the
dispensed doses of OAT opioids, patients were catego-
rized into three groups based on the OAT opioid dose
ratio: < 0.5, 0.5–1, and > 1. Patients who were dispensed
an OAT opioid dose > 1 indicated a daily dose above the
mean dose during OAT.
Analysis strategy according to the objectives
Dispensation rates were defined as all patients on OAT who
were dispensed at least one opioid analgesic per year divided
by all included patients who were dispensed an OAT opioid
the same year. We divided opioid analgesics into two drug
groups based on their potency when presenting the dispen-
sation rates: weak opioid analgesics (codeine, tramadol, and
tapentadol) and strong opioid analgesics (all opioid analge-
sics apart from codeine, tramadol, and tapentadol). We
presented the total dispensed doses of opioid analgesics as a
mean daily dose per patient per year stated in OMEQ.
Using logistic regression models, we evaluated the
association between being dispensed an opioid analgesic
and the number and type of dispensed OAT opioids, as
well as the OAT opioid dose ratio, the patient’s age and
gender, and whether they had chronic pain or were on
palliative care. The models were run with all included
patients per year and those who had 13 or more dispen-
sations of OAT opioids per year. Concerning the latter
population, we investigated whether the associations
were consistent for those who frequently dispensed
OAT opioids when compared with including all patients.
All patients who discontinued OAT were identified.
For these patients, the dispensations of opioid analgesics
were categorized into three periods: 180–90 days before,
90 days before, and 90 days after the discontinuation
date. The interval 180 to 90 days before the discontinu-
ation date was defined as the baseline. The dispensation
rates were defined as all patients who dispensed an
opioid analgesic in the periods divided by the number of
patients who discontinued OAT. The dispensed doses of
opioid analgesics per day were calculated by dividing the
number of dispensed OMEQ for each period by 90 days.
The calculation of OMEQ dose was similar to when
calculating the OMEQ dose per year. The mean OMEQ
dose before and after discontinuation were compared.
Statistical analyses
The means, median, percentiles, percentage, 95% confi-
dence interval (CI), odds ratio (OR), and p-value are
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presented. The paired t-test was used to compare the
mean doses of dispensed opioid analgesics before and
after the discontinuation date of OAT. Multivariate ana-
lyses for categorical variables were performed per year
by creating logistic regression models. In these models,
the dependent categorical variable was being dispensed
an opioid analgesic during a calendar year. Age groups,
gender, having chronic pain, being on palliative care, the
type of OAT opioid, the number of dispensed OAT
opioids, and the OAT opioid dose ratio were handled as
independent and categorical variables. The level of
statistical significance was set to p < 0.05. SPSS version
24 was used for all statistical analyses.
Ethical considerations
The Regional Committee for Medical and Health Re-
search Ethics, REC vest, Norway, approved the use of
registry data for the study (approval number 2018/939/
REK Vest, June 19, 2018). No informed consent from in-
cluded patients was necessary.
Results
Basic characteristics
A total of 10,371 patients were dispensed at least one OAT
opioid from pharmacies in Norway in the period from 2013
to 2017. In 2017, 69% were men, and the mean age was 45
years. Buprenorphine or buprenorphine-naloxone was dis-
pensed to 61% of the patients (Table 1). During the study
period, 737 patients were dispensed at least one reimbursed
drug due to palliative care, and 2011 patients received at
least one reimbursed drug due to chronic pain. A total of
692 patients died during the study period.
Dispensation rates and mean daily doses of opioid
analgesics
The proportion of OAT patients who were dispensed at
least one weak or strong opioid analgesic was 18% in
2017. In the same year, 13% were dispensed at least one
weak opioid analgesic, and 7% were dispensed at least
one strong opioid analgesic. The most dispensed weak
opioid analgesic was codeine (9% in 2017), and the most
dispensed strong opioid analgesic was oxycodone (3% in
2017) (Table 2). Similar results were seen in the period
2013–2016. The mean daily dose of dispensed opioid an-
algesics was 51mg OMEQ per day in 2013 and 29 mg
OMEQ per day in 2017.
Factors associated with being dispensed an opioid
analgesic
We found that being dispensed an opioid analgesic was
associated with being female, on palliative care, having
chronic pain, and dispensed OAT opioids less than every
second month (≤ 6 dispensations per year), compared
with being dispensed OAT opioids at least weekly (≥ 52
dispensations per year) when including all patients in
2017 (Table 3). In addition, we found that being dis-
pensed an opioid analgesic was associated with having
an OAT opioid dose ratio below 0.5 compared with an
OAT opioid dose ratio above 1.0. Similar results were
seen in the period 2013–2016 (Additional file 4). For
patients who were dispensed OAT opioids at least
monthly (13 or more dispensations per year), we found
that the independent variables (gender, age group,
having chronic pain, being on palliative care, the type of
dispensed OAT opioids, and OAT opioid dose ratio)
were substantially unchanged when including all patients
(Additional file 5).
The dispensation rates and mean daily doses of opioid
analgesics among patients who discontinued OAT
A total of 693 patients discontinued OAT during the
period January 1, 2017 to September 30, 2017. Of these,
111 (16%) patients were dispensed an opioid analgesic in
the last 180 days before the discontinuation date (Table 4).
In the 90 days following the discontinuation date, 122
(18%) were dispensed an opioid analgesic. Patients who
were only dispensed opioid analgesics in the last 90 days
before the discontinuation date (not at baseline) increased
the mean daily dose of dispensed opioid analgesic from
38mg OMEQ to 347mg OMEQ in the 90 days following
the discontinuation date (Δ mean 308, 95% CI: 22–594,
p = 0.04). For patients who only were dispensed an opioid
analgesic in the 90 days after the discontinuation date, the
mean dose of opioid analgesic was 91mg OMEQ per day.
Discussion
The proportion of patients on OAT in Norway who
were dispensed an opioid analgesic in the study period
was 18% yearly. By comparison, 11% were dispensed an
opioid analgesic in the general Norwegian population in
2017 [28]. The proportion of OAT patients who were
dispensed weak opioid analgesics was higher than those
dispensed strong opioid analgesics. Oxycodone was the
most dispensed strong opioid analgesic, and codeine was
the most dispensed weak opioid analgesic. The dispensa-
tion of an opioid analgesic was associated with being:
female, on palliative care, having chronic pain, dispensed
OAT opioids less than every second month compared
with no less than weekly dispensations, and dispensed
an OAT opioid dose below half the recommended mean
dose compared with a dose above the mean recommended
dose. Discontinuation of OAT did not substantially affect
the proportion of patients who were dispensed opioid
analgesic. However, doses of dispensed opioid analgesics
were higher among those who initiated opioid analgesics
the last 90 days before discontinuation.
18% of patients on OAT were dispensed at least one
opioid analgesic in 2017, which was an increase from
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12% compared with the period from 2007 to 2008 in the
OAT population [8]. The increase of dispensed opioid
analgesics may be related to changes in the Norwegian
eligibility criteria that grants OAT. During recent years,
patients with opioid dependence using street drugs
besides opioids have been offering OAT rehabilitation in
terms of increasing the coverage of OAT rehabilitation
and reducing opioid overdoses and complications
associated with injecting street opioids [22, 29, 30]. In
addition, patients with chronic pain who develop an
opioid dependence through long-term dispensations of
opioid analgesics are offered OAT if opioid discontinu-
ation is unsuccessful. By granting OAT to a broader
specter of patients with opioid dependence, the OAT
population may have become more physical and psychi-
atrically comorbid, which may explain the increase of
Table 1 Basic characteristics of patients who were dispensed an OAT opioid
Basic characteristics 2013 2014 2015 2016 2017
No. (%) No. (%) No. (%) No. (%) No. (%)
Patients 7709 7914 7958 7804 7709
Deaths 165 151 138 114 124
Patients, excluded deaths 7544 7763 7820 7690 7585
Age
≤ 25 211 (3) 185 (2) 171 (2) 135 (2) 120 (2)
26–35 1590 (21) 1570 (20) 1551 (20) 1403 (18) 1333 (18)
36–45 2724 (36) 2730 (35) 2605 (33) 2508 (33) 3292 (32)
46–55 2283 (30) 2449 (32) 2544 (33) 2540 (33) 2548 (34)
≥ 56 736 (10) 829 (11) 949 (12) 1104 (14) 1192 (16)
Mean (SD) 43 (10) 44 (10) 44 (10) 44 (10) 45 (10)
Gender
Male 5221 (69) 5390 (69) 5430 (69) 5354 (70) 5245 (69)
Female 2323 (31) 2373 (31) 2390 (31) 2336 (30) 2340 (31)
OAT opioidsa
Methadone (included levomethadone) 3406 (45) 3264 (42) 3216 (41) 3066 (40) 2981 (39)
Buprenorphine (included combination
with naloxone)
4138 (55) 4499 (58) 4604 (59) 4624 (60) 4604 (61)
Dispensed opioid analgesics
- All 1430 (19) 1424 (18) 1400 (18) 1382 (18) 1359 (18)
- Strong opioid analgesic 542 (7) 518 (7) 490 (6) 534 (7) 526 (7)
- Weak opioid analgesic 1089 (14) 1078 (14) 1066 (14) 1011 (13) 997 (13)
Dose of dispensed opioid analgesics
(in OMEQ)
- mean (mg/year) 18,538 17,399 8963 9361 10,723
- mean (mg/day/year) 51 48 25 26 29
- median (mg/year) 450 400 400 500 500
- median (mg/day/year) 1 1 1 1 1
- 25 percentile (mg/year) 86 75 90 100 100
- 25 percentile (mg/day/year) 0 0 0 0 0
- 75 percentile (mg/year) 4478 3321 2616 2891 3500
- 75 percentile (mg/day/year) 12 9 7 8 10
Patients on palliative careb 737
Patients with chronic painc 2011
No.: Number of patients; OAT Opioid agonist therapy, OMEQ Oral morphine equivalents, SD Standard deviation
a The type of OAT opioid that was dispensed on the last dispensation per year
b Patients who were dispensed drugs that were reimbursed due to palliative care in the study period
c Patients who were dispensed a drug that was reimbursed due to chronic pain in the study period. Patients who were dispensed drugs that were reimbursed for
palliative care and chronic pain were classified as ‘patients on palliative care’
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dispensed opioid analgesics during the last decade [22].
However, the dispensation rates of opioid analgesics in
the Norwegian OAT population were substantially low
compared with studies on the OAT population in
Canada, which shows a prevalence of dispensed opioid
analgesics between 18 and 34% [9, 23].
An OAT opioid dose below half the recommended
mean dose was associated with being dispensed an opi-
oid analgesic. This finding may point out that a low dose
of OAT opioids does not adequately protect against
craving and opioid withdrawal, causing concomitant
dispensations of opioid analgesics. Kurdyak et al. [23]
assessed the dispensations of opioid analgesics in an
OAT population. The authors found that opioid analge-
sics were more often dispensed by prescribers that were
not responsible for OAT rehabilitation [23]. A lack of
optimal OAT dose may be a possible explanation for why
patients seek other prescribers to be dispensed opioid
analgesics. This is of particular importance to ensure an
adequate OAT opioid dose to stabilize opioid dependence
and prevent dispensations of opioid analgesics to treat
opioid withdrawal and cravings. Therefore, guidelines
preferably recommend the long-acting opioids methadone
or buprenorphine during OAT rehabilitation [29, 31, 32].
Patients on OAT that have chronic pain or on pallia-
tive care are associated with being dispensed opioid
analgesics. The results are consistent with results seen in
a comparable study on OAT patients [9] and the overall
Norwegian population [33]. In general, there is a lack of
knowledge showing a persistent analgesic effect of long-
term use of opioid analgesics on chronic pain [34]. A
recent study showed that OAT patients with chronic
pain were associated with chronic hepatitis C virus
infection, mental health disorder, low-income status, and
alcohol dependence compared with the general OAT
population [35]. These medical and psychosocial comor-
bidities may influence and exacerbate the patient’s sub-
jective experience of pain, making the pain management
with opioid analgesics particularly challenging [36, 37].
On the other hand, OAT patients on palliative care can
improve quality of life if adequate management of pain
and opioid dependence is provided [38]. A close collab-
oration between health professionals in several health
and social care teams can be the key to success among
patients with chronic pain and those on palliative care,
particularly if there is an ongoing use of illegal drugs.
Handling opioid analgesics for these patients with
complex medical and psychosocial conditions is not
discussed in the current worldwide OAT guidelines
[39–41]. Nevertheless, our findings point out that the
proportion of Norwegian OAT patients above 56 years
increased from 10 to 16% from 2013 to 2017. This
increase in elderly OAT patients may predict a need
in the next coming decades for guidelines on how to
handle chronic pain and palliative care for such pa-
tients. In addition, this emphasizes the importance of
customizing the OAT for ensuring further sufficient
opioid agonist therapy and adequate pain manage-
ment in this population [42–44].
Discontinuing OAT did not substantially change
the number of patients who were dispensed opioid
analgesics. However, initiating dispensations of opioid
Table 2 The proportion of patients who were dispensed an opioid analgesic
Year 2013 2014 2015 2016 2017
Opioid analgesics No. (%*) No. (%*) No. (%*) No. (%*) No. (%*)
Number of patients 7544 7763 7820 7690 7585
Strong opioid analgesics
Oxycodone 234 (3) 226 (3) 205 (3) 231 (3) 246 (3)
Morphine 184 (2) 143 (2) 120 (2) 134 (2) 149 (2)
Fentanyl 79 (1) 58 (1) 39 (0) 11 (0) 34 (0)
Buprenophine (non OAT) 129 (2) 138 (2) 154 (2) 163 (2) 145 (2)
Ketobemidone 51 (1) 55 (1) 48 (1) 49 (1) 31 (0)
Pethidine 6 (0) 6 (0) 5 (0) < 5 (0) 5 (0)
Hydromorphone 12 (0) 5 (0) < 5 (0) < 5 (0) < 5 (0)
Weak opioid analgesics
Codeine 822 (11) 799 (10) 781 (10) 730 (9) 690 (9)
Tramadol 392 (5) 397 (5) 398 (5) 375 (5) 417 (5)
Tapentadol 14 (0) 7 (0) 6 (0) 10 (0) 10 (0)
The table displays the proportion of patients on OAT who were dispensed a weak and a strong opioid analgesics in the period 2013–2017. We only included
opioid analgesics that had marketing authorization in Norway in the study period
No.: Number of patients, OAT Opioid agonist therapy
* Percent of patients who were dispensed an OAT opioid
Vold et al. BMC Health Services Research          (2020) 20:668 Page 6 of 10
analgesics during the 90 days prior to the discontinu-
ation date increased the doses of dispensed opioid
analgesics significantly when compared with the dispensed
doses during the 90 days following the discontinuation date.
For these patients, one can assume that opioid analgesics
were typically dispensed to suppress opioid withdrawal and
craving due to the OAT opioid dose’s rapid tapering off.
Planning an OAT opioid dose’s long-term tapering off at
discontinuation is essential to prevent increased mor-
tality, should the patient relapse to street opioids, and
limit dispensations of opioid analgesics to treat opioid
withdrawal [14].
Strengths and limitations
The use of national registry data has some clear
strengths, such as capturing whole cohorts of the studied
populations. Pharmacy records are considered more
valid than both medical records and data collected from
questionnaires and interviews. Because practically all
dispensed drugs are registered in the NorPD database,
the completeness and precision of all received informa-
tion is high, and the potential for information bias is
low.
This study does however have some limitations. First,
about 10% of the OAT patients were not registered by
NorPD. These patients received OAT opioids from
outpatient clinics in primary health care or specialized
health care. Some of these outpatient clinics ordered
OAT opioids directly from pharmacies without any link-
age to a personal identification number. These patients
were lost in this study [22]. Second, the annual self-
reporting survey of OAT suggested that the mean num-
ber of dispensations of OAT opioids were four times a
week [22], which did not wholly match our estimates.
To adjust for the uncertainty concerning which was
most correct, we used the OAT opioid dose ratio
Table 3 Logistic regression of factors associated with being dispensed an opioid analgesic in 2017
Patients who had ≥1 dispensation of an
opioid analgesic
N = 1359
cOR aOR (95% CI) p-value
Age
≤ 25 1.00 (ref.) 1.00 (ref.)
26–35 0.93 1.01 (0.60–1.70) .964
36–45 0.90 1.00 (0.60–1.66) .985
46–55 1.17 1.31 (0.78–2.18) .304
≥ 56 1.55 1.59 (0.95–2.68) .080
Gender
Male 1.00 (ref.) 1.00 (ref.)
Female 1.64 1.44 (1.27–1.64) < .001
Patients on palliative care 5.00 6.08 (4.67–7.92) < .001
Patients with chronic pain 3.30 3.64 (3.16–4.19) < .001
The number of dispensations of OAT opioids per year
≥ 52 (at least weekly) 1.00 (ref.) 1.00 (ref.)
13–51 (at least monthly) 1.10 1.10 (0.88–1.37) .423
7–12 (less than monthly) 1.35 1.10 (0.85–1.43) .454
1–6 (less than every second month) 1.98 1.44 (1.07–1.93) .016
OAT opioidsa
Buprenorphine/Buprenoprhine-naloxone 1.00 (ref.) 1.00 (ref.)
Methadone/Levomethadone 1.04 0.96 (0.84–1.10) .542
OAT opioid dose ratio per dayb
> 1 1.00 (ref.) 1.00 (ref.)
0.5–1 0.85 0.95 (0.80–1.11) .497
< 0.5 1.61 1.69 (1.41–2.03) < .001
The table displays the association between being dispensed an opioid analgesic and age groups, gender, palliative care, chronic pain, the number of
dispensations of OAT opioids, the type of dispensed OAT opioid, and the OAT opioid dose ratio among all patients who were dispensed an OAT opioid in 2017
aOR adjusted odds ratio, cOR crude odds ratio, CI confidence interval, OAT opioid agonist therapy
a The type of OAT opioid that was dispensed on the last dispensation
b We defined the OAT opioid dose ratio as a mean daily dose of dispensed OAT opioids divided by mean recommended daily dose of OAT opioids (18 mg
buprenorphine or 18/4.5 mg buprenorphine/naloxone, 90mg methadone or 45 mg levomethadone). A ratio of one indicated that patients were dispensed a mean
daily dose of OAT opioids equal to the mean recommended dose per day
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measuring the mean recommended daily dose to comple-
ment our results. Third, the NorPD only receives informa-
tion about dispensed drugs, and we could not know
whether the drugs have been consumed or whether the
patients were using illegal drugs concomitantly. Fourth,
the dispensations of opioid analgesics may have con-
founders. Therefore, we adjusted for two potentially
strong confounders by identifying patients who were dis-
pensed drugs on reimbursement codes for chronic pain
and palliative care in the database. Nevertheless, a minor
part of the medical indications for dispensed drugs was
available by using reimbursement codes in NorPD [28].
Conclusion
18% of Norwegian OAT patients per year were dis-
pensed an opioid analgesic in the period 2013–2017. A
substantial proportion of those who were dispensed
opioid analgesics had an OAT opioid dose less than half
Table 4 Dispensation of opioid anagetics among patients who discontinued OAT
The table displays the mean doses of dispensed opioids analgesics among patients who discontinued OAT. Patients’ opioid dispensations were analyzed in three
periods according to the OAT disconatinuation date: 180–90 days before, 90 days before, and 90 days after the discontinuation date. All doses of dispensed opioid
analgesics were summarized in each period and converted to OMEQ. The mean, median, 25 percentile and 75 percentile were calculated for the three periods.
For those who were dispensed opioid analgesics in the periods before and after the discontinuation date, we have used a paired t-test for calculating differences
in dispensed doses of the opioid analgesics.
CI Confidence interval, Df Degree of freedom, OAT Opioid agonist therapy, OMEQ Oral morphine equivalents.
1) The change in opioid analgesic dose when comparing dispensed doses before discontinuation with dispensed doses after discontinuation
2) Paired t-test of the mean daily dose at the 90 days after discontinuation compared with the mean daily dose at baseline (180 to 90 days before discontinuation). Df = 37
3) Paired t-test of the mean daily dose at the last 90 days before discontinuation compared with the mean daily dose at the 90 days after discontinuation. Df = 12
4) Paired t-test of the mean daily dose at the 90 days after discontinuation compared with the mean daily dose at baseline (180 to 90 days before discontinuation). Df = 8
Vold et al. BMC Health Services Research          (2020) 20:668 Page 8 of 10
the recommended mean dose, were on palliative care, or
had chronic pain. In addition, discontinuing OAT in-
creased the doses of dispensed opioid analgesics among
patients that initiated opioid analgesics the last 90 days
before discontinuation. A reduction in the proportion of
OAT patients dispensed opioid analgesics may be
achieved by increasing the OAT opioid dose for patients
taking low-dose OAT opioids and facilitating it for those
with chronic pain and on palliative care. For patients
who discontinue OAT, an extended period of tapering
off can reduce the dispensations of opioid analgesics
after discontinuation.
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